Science Corporation is a clinical-stage medical technology company developing implantable systems for sensory restoration and neural interfacing. Its work spans retinal prosthetics, biohybrid neural interfaces, and organ-support technologies, with development conducted within regulated clinical and translational pathways rather than consumer applications.

One of the company’s primary clinical programs is PRIMA, a subretinal prosthetic system intended for people with advanced degenerative retinal diseases, including atrophic dry age-related macular degeneration. In these conditions, photoreceptors are lost while downstream retinal neurons remain partially functional. PRIMA is designed to bypass damaged rods and cones by directly stimulating the remaining retinal cells to transmit visual information to the brain. The system is currently being evaluated in clinical trials.

PRIMA consists of a light-powered implant placed beneath the retina and an external pair of glasses equipped with a camera and infrared projector. Visual input captured by the camera is converted into infrared light patterns projected onto the implant, providing both power and data. The implant contains 378 independently controlled pixels arranged in a honeycomb pattern; when illuminated, each pixel activates a local electrode that stimulates the adjacent retinal tissue. Beyond PRIMA, Science Corporation is also developing biohybrid neural interfaces based on engineered living neurons, as well as perfusion technologies aimed at extending organ viability in transplantation and critical care settings.